Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.37 |
| ▸ | ARG1 | P05089 | 1/20 | 0.34 |
| ▸ | ARG2 | P78540 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6059520 | 1.00 | GGT1 (0.37) | GGT1ARG1ARG2BLMKDM4E | |
| SCHEMBL5834081 | 1.00 | GGT1 (0.37) | GGT1ARG1ARG2BLMKDM4E | |
| SCHEMBL5839218 | 1.00 | GGT1 (0.37) | GGT1ARG1ARG2BLMKDM4E | |
| SCHEMBL909828 | 0.84 | GGT1 (0.42) | GGT1ARG1ARG2BLM | |
| SCHEMBL7074561 | 0.84 | GGT1 (0.35) | GGT1ARG1ARG2 | |
| SCHEMBL7067865 | 0.84 | GGT1 (0.35) | GGT1ARG1ARG2 | |
| SCHEMBL909829 | 0.84 | GGT1 (0.42) | GGT1ARG1ARG2BLM | |
| SCHEMBL7126761 | 0.84 | GGT1 (0.35) | GGT1ARG1ARG2 | |
| SCHEMBL1843909 | 0.84 | GGT1 (0.42) | GGT1ARG1ARG2BLM | |
| SCHEMBL7127756 | 0.84 | GGT1 (0.35) | GGT1ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256199-A1 | 2-Amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2005-11-17 | — | — | US | claimed |
| US-6756406-B2 | ANTIARTHRITIC AGENTS; RHEUMATIC DISEASES; OSTEOARTHRITIS; INHIBITION OF THE INDUCIBLE NITRIC OXIDE SYNTHASE - INDUCED AFTER ACTIVATION OF VASCULAR SMOOTH MUSCLE, MACROPHAGES, ENDOTHELIAL CELLS BY ENOTOXIN AND CYTOKINES | PHARMACIA CORPORATION | 2004-06-29 | — | — | US | claimed |
| US-20040077639-A1 | Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor | MANNING PAMELA T (US) | 2004-04-22 | — | — | US | claimed |
| US-20180214430-A1 | Selective Inhibitors Of i-NOS For Use Against Viral Infection | UCL BUSINESS PLC (GB) | 2018-08-02 | — | — | US | disclosed |
| US-7012098-B2 | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers | PHARMACIA CORPORATION (US) | 2006-03-14 | — | — | US | disclosed |
| US-20050256199-A1 | 2-Amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20040127569-A1 | Methods for treatment and prevention of gastrointestinal conditions | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-6756406-B2 | ANTIARTHRITIC AGENTS; RHEUMATIC DISEASES; OSTEOARTHRITIS; INHIBITION OF THE INDUCIBLE NITRIC OXIDE SYNTHASE - INDUCED AFTER ACTIVATION OF VASCULAR SMOOTH MUSCLE, MACROPHAGES, ENDOTHELIAL CELLS BY ENOTOXIN AND CYTOKINES | PHARMACIA CORPORATION | 2004-06-29 | — | — | US | disclosed |
| US-20040087653-A1 | Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor | MANNING PAMELA T (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040077639-A1 | Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor | MANNING PAMELA T (US) | 2004-04-22 | — | — | US | disclosed |
| US-20030013702-A1 | Agents and methods for treatment of cancer | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214430-A1 | Selective Inhibitors Of i-NOS For Use Against Viral Infection | NOS2, NOS1, NOS3 | GGT1 438/4885ARG1 80/4885ARG2 50/4885 |
| US-20030013702-A1 | Agents and methods for treatment of cancer | FAP, APC, PTGIS | GGT1 141/4885ARG1 482/4885ARG2 315/4885 |
| US-20040087653-A1 | Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor | NOS2, NOS1, PDE3A | GGT1 135/4885ARG1 21/4885ARG2 11/4885 |
| US-20040077639-A1 | Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor | NOS2, NOS1, NOS3 | GGT1 205/4885ARG1 9/4885ARG2 4/4885 |
| US-20050256199-A1 | 2-Amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | ALOX12, ALOX5, ALOX15 | GGT1 879/4885ARG1 200/4885ARG2 110/4885 |
| US-20040127569-A1 | Methods for treatment and prevention of gastrointestinal conditions | SI, NOS2, NOS3 | GGT1 57/4885ARG1 13/4885ARG2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.